What is Kesimpta's loading phase?
Kesimpta (ofatumumab), an injection for relapsing multiple sclerosis, starts with a loading phase of three weekly 20 mg subcutaneous doses (days 1, 8, and 15). After that, patients switch to a 20 mg maintenance dose every 4 weeks starting at week 4.[1]
How is the full dosing schedule structured?
- Weeks 0-3 (loading): 20 mg once weekly for 3 doses.
- Week 4 onward (maintenance): 20 mg every 4 weeks.
This schedule reduces relapse rates and disability progression, per clinical trials like ASCLEPIOS I/II.[1][2]
Why does Kesimpta use a loading phase?
The initial weekly doses quickly build ofatumumab levels in the body to target CD20-positive B cells effectively from the start. This front-loading achieves therapeutic concentrations faster than monthly dosing alone, minimizing early disease activity.[2]
How long until steady-state levels?
Steady-state plasma concentrations are reached after about 4-6 months of maintenance dosing, though the loading phase accelerates onset of action within weeks.[2]
What if a loading dose is missed?
Administer the missed dose as soon as possible, then resume the schedule. If it's near the next dose, skip it to avoid doubling up.[1]
How does Kesimpta's loading phase compare to other MS infusions?
| Drug | Loading Phase | Maintenance |
|------|---------------|-------------|
| Kesimpta (subQ) | 3 weekly doses | Every 4 weeks |
| Ocrevus (IV) | None (two 300 mg doses 2 weeks apart at start) | Every 6 months |
| Briumvi (IV) | None (two 100 mg doses 2 weeks apart) | Every 24 weeks |
| Mavenclad (oral) | 2 courses of 4-5 daily doses over 2 years | None |
Kesimpta's self-administered subQ format offers more frequent home dosing during loading than IV competitors.[3][1]
[1]: Kesimpta Prescribing Information (Novartis)
[2]: FDA Approval Summary for Kesimpta
[3]: DrugPatentWatch.com - Kesimpta Patent Status